SciSparc Ltd. (SPRC) has released an update.
SciSparc Ltd., in collaboration with Clearmind Medicine Inc., has announced the publication of an international patent application for a novel MDMA-based treatment aimed at improving safety and efficacy in mental health and addiction therapies. Their combined approach seeks to address FDA concerns by integrating MDMA with N-Acylethanolamines, promising advancements in clinical treatments of mental disorders and addictions. SciSparc, a clinical-stage pharmaceutical company, continues to focus on cannabinoid-based pharmaceuticals, while Clearmind concentrates on psychedelic-derived therapeutics for underserved health problems.
For further insights into SPRC stock, check out TipRanks’ Stock Analysis page.
